Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Clinical guidelines continue to move away from routine prostate specific antigen screening (PSA), once a widespread medical practice. A curious difference exists between early prostate cancer and early breast cancer. While randomized trials of therapy in early breast cancer continue to show overall survival benefit, this is not the case in prostate cancer, where prostatectomy was no better than observation in a recent trial, and where early androgen deprivation is no better than late androgen deprivation. Here, I make the case that prostate cancer screening contributes so greatly to over diagnosis that even treatment trials yield null results due to contamination with non-life threatening disease.

Original languageEnglish (US)
Pages (from-to)71-73
Number of pages3
JournalMedical Hypotheses
Volume93
DOIs
StatePublished - Aug 1 2016

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?'. Together they form a unique fingerprint.

  • Cite this